Web Results

www.openaccessjournals.com/articles/clinical-trials-of-idiopathic-pulmonary-fibrosis-choosing-the-right-primary-end-point.pdf

Drug development in IPF has proven challenging with exceedingly high clinical trial failure rates. With the goal of delivering safe and effective therapies to our ...

blogs.sciencemag.org/pipeline/archives/2019/09/17/quietly-another-drug-candidate-disappears

Sep 17, 2019 ... Let's start with this: there's a terrible disease called IPF, idiopathic ... here, Biogen had actualy developed the program initially, outlicensed it to&n...

www.technologynetworks.com/drug-discovery/news/two-targeted-therapies-developed-for-idiopathic-pulmonary-fibrosis-342774

Nov 13, 2020 ... ... Professor of Chemistry and Presidential Scholar for Drug Discovery, has led a team to develop two targeted therapies for people with IPF.

pubs.rsc.org/en/content/chapterhtml/2020/bk9781788015103-00001?isbn=978-1-78801-510-3

... of drug development outside of cancer indications. This review will focus on the role of TGFβ in the indications of idiopathic pulmonary fibrosis (IPF) and ...

raremark.com/idiopathic-pulmonary-fibrosis-ipf/articles/idiopathic-pulmonary-fibrosis-treatment-and-management--857

The drug also helps cut down on the number of acute exacerbations that IPF ... What are some advances and treatments for IPF that are in development?

www.mayo.edu/research/clinical-trials/diseases-conditions/pulmonary-fibrosis

IPF is a chronic, progressive, irreversible, and usually fatal lung disease of ... The purpose of this study is to determine if study drug (BMS-986020) dose of 600 mg ... blood c...

www.bonac.com/global/en/research/development/ipf

A new treatment drug for IPF has been developed in the recent years, and while this drug is reported to have an effect in suppressing the progression of the ...

www.blf.org.uk/support-for-you/idiopathic-pulmonary-fibrosis-ipf/treatment

Medication to slow lung scarring. Currently 2 anti-fibrotic drugs can be prescribed . pirfenidone; nintedanib. Both slow down the development of scar tissue in the ...

lungdiseasenews.com/2018/02/02/fda-approves-prometics-plan-for-phase-3-trial-of-its-pulmonary-fibrosis-therapy

Feb 2, 2018 ... Read about the U.S. Food and Drug Administration approving ... Prometic is developing it not only as a potential treatment for IPF, but also for ...

investor.fibrogen.com/news-releases/news-release-details/fibrogens-fg-3019-granted-us-orphan-drug-designation-treatment

IPF is a progressive and fatal lung disease for which there are no FDA-approved therapies. FG-3019 was developed to inhibit the activity of CTGF, a matricellular ...